

Cyklus EHK: IFT1/26 - Imunofenotypizace

Stop termín: 27.4.2026

Nastavení: skupiny - R (výrobce reagentů); minimální četnost skupin n = 5

RoM = robustní průměr

SD = směrodatná odchylka

CV = variační koeficient

N_{tot} = celkový počet výsledkůN_{out} = počet výsledků vyloučených před výpočtem

AV = vztažná hodnota

CVP = konsenzus všech účastníků

U_{AV} = rozšířená nejistota vztažné hodnoty (k = 2)D_{max} = přijatelný rozdíl

LL = dolní mez

UL = horní mez

N_{eva} = počet hodnocených výsledkůN_{suc} = počet úspěšných výsledkůS_{rel} = relativní úspěšnost

| Zkouška Vzorek Skupina | [jednotka] | RoM | SD | CV [%] | N _{tot} | N _{out} | Srovnatelnost | | | | | N _{eva} | N _{suc} | S _{rel} [%] | |
|----------------------------------|------------|------|------|-----------|------------------|------------------|-----------------------|-----------------|------------------|-----|------|------------------|------------------|-------------------------|-----|
| | | | | | | | AV | U _{AV} | D _{max} | LL | UL | | | | |
| (253) T lymfocyty (CD3+) | [%] | | | | 101 | | | | | | | 101 | 101 | 100 | |
| Vzorek A | | 73,1 | 1,4 | 1,9 | 101 | | CVP | 73,1 | 0,35 | 7% | 67,9 | 78,3 | 101 | 101 | 100 |
| (12) Beckman Coulter | | 73,1 | 1,6 | 2,2 | 61 | 0 | | | | | | | 61 | | |
| (88) Becton Dickinson | | 73,1 | 0,8 | 1,1 | 12 | 0 | | | | | | | 12 | | |
| (177) Mindray | | 72,5 | 1,1 | 1,5 | 6 | 0 | | | | | | | 6 | | |
| (190) Exbio Praha | | 73,1 | 1,2 | 1,7 | 16 | 0 | | | | | | | 16 | | |
| Ostatní | | | | | 6 | 0 | | | | | | | 6 | | |
| | | | | | | | 3x 36, 3x 999 | | | | | | | | |
| Vzorek B | | 89 | 1,3 | 1,5 | 101 | | CVP | 89 | 0,33 | 7% | 82,7 | 95,3 | 101 | 101 | 100 |
| (12) Beckman Coulter | | 89 | 1,3 | 1,5 | 61 | 0 | | | | | | | 61 | | |
| (88) Becton Dickinson | | 89,6 | 1,8 | 2 | 12 | 0 | | | | | | | 12 | | |
| (177) Mindray | | 87,8 | 0,59 | 0,68 | 6 | 0 | | | | | | | 6 | | |
| (190) Exbio Praha | | 88,9 | 1,7 | 1,9 | 16 | 0 | | | | | | | 16 | | |
| Ostatní | | | | | 6 | 0 | | | | | | | 6 | | |
| | | | | | | | 3x 36, 3x 999 | | | | | | | | |
| (254) Th lymfocyty (CD4+) | [%] | | | | 101 | | | | | | | 101 | 100 | 99 | |
| Vzorek A | | 41,2 | 1,3 | 3,2 | 101 | | CVP | 41,2 | 0,32 | 10% | 37 | 45,4 | 101 | 100 | 99 |
| (12) Beckman Coulter | | 41,2 | 1,5 | 3,5 | 61 | 0 | | | | | | | 61 | | |
| (88) Becton Dickinson | | 40,8 | 1,5 | 3,6 | 12 | 0 | | | | | | | 12 | | |
| (177) Mindray | | 41,4 | 1,7 | 4 | 6 | 0 | | | | | | | 6 | | |
| (190) Exbio Praha | | 41,6 | 0,73 | 1,8 | 14 | 0 | | | | | | | 14 | | |
| Ostatní | | | | | 8 | 0 | | | | | | | 8 | | |
| | | | | | | | 3x 36, 2x 166, 3x 999 | | | | | | | | |
| Vzorek B | | 65,3 | 1,4 | 2,2 | 101 | | CVP | 65,3 | 0,35 | 10% | 58,7 | 71,9 | 101 | 101 | 100 |
| (12) Beckman Coulter | | 65,4 | 1,5 | 2,3 | 61 | 0 | | | | | | | 61 | | |
| (88) Becton Dickinson | | 65,2 | 1,7 | 2,7 | 12 | 0 | | | | | | | 12 | | |
| (177) Mindray | | 66 | 2,1 | 3,2 | 6 | 0 | | | | | | | 6 | | |
| (190) Exbio Praha | | 65,4 | 1,1 | 1,7 | 14 | 0 | | | | | | | 14 | | |
| Ostatní | | | | | 8 | 0 | | | | | | | 8 | | |
| | | | | | | | 3x 36, 2x 166, 3x 999 | | | | | | | | |
| (255) T lymfocyty (CD8+) | [%] | | | | 101 | | | | | | | 101 | 100 | 99 | |
| Vzorek A | | 29,5 | 0,86 | 2,9 | 101 | | CVP | 29,5 | 0,21 | 17% | 24,4 | 34,6 | 101 | 101 | 100 |
| (12) Beckman Coulter | | 29,5 | 1 | 3,4 | 61 | 0 | | | | | | | 61 | | |
| (88) Becton Dickinson | | 29,8 | 0,8 | 2,7 | 12 | 0 | | | | | | | 12 | | |
| (177) Mindray | | 29,4 | 0,52 | 1,8 | 6 | 0 | | | | | | | 6 | | |
| (190) Exbio Praha | | 29,7 | 0,77 | 2,6 | 14 | 0 | | | | | | | 14 | | |
| Ostatní | | | | | 8 | 0 | | | | | | | 8 | | |
| | | | | | | | 3x 36, 2x 166, 3x 999 | | | | | | | | |
| Vzorek B | | 20,8 | 0,89 | 4,3 | 101 | | CVP | 20,8 | 0,22 | 17% | 17,2 | 24,4 | 101 | 100 | 99 |
| (12) Beckman Coulter | | 20,8 | 0,89 | 4,3 | 61 | 0 | | | | | | | 61 | | |
| (88) Becton Dickinson | | 21,8 | 1 | 4,7 | 12 | 0 | | | | | | | 12 | | |
| (177) Mindray | | 20,7 | 0,44 | 2,1 | 6 | 0 | | | | | | | 6 | | |
| (190) Exbio Praha | | 20,7 | 0,59 | 2,9 | 14 | 0 | | | | | | | 14 | | |
| Ostatní | | | | | 8 | 0 | | | | | | | 8 | | |
| | | | | | | | 3x 36, 2x 166, 3x 999 | | | | | | | | |
| (256) B lymfocyty | [%] | | | | 101 | | | | | | | 101 | 99 | 98 | |
| Vzorek A | | 16 | 1 | 6,3 | 101 | | CVP | 16 | 0,25 | 30% | 11,2 | 20,8 | 101 | 100 | 99 |
| (12) Beckman Coulter | | 15,9 | 1,1 | 7 | 61 | 0 | | | | | | | 61 | | |
| (36) Immunotech | | 15,1 | 1,1 | 7,4 | 5 | 0 | | | | | | | 5 | | |
| (88) Becton Dickinson | | 16,6 | 0,81 | 4,9 | 12 | 0 | | | | | | | 12 | | |
| (177) Mindray | | 16 | 0,96 | 6 | 6 | 0 | | | | | | | 6 | | |
| (190) Exbio Praha | | 16,2 | 0,56 | 3,4 | 14 | 0 | | | | | | | 14 | | |
| Ostatní | | | | | 3 | 0 | | | | | | | 3 | | |
| | | | | | | | 3x 999 | | | | | | | | |
| Vzorek B | | 7,33 | 0,58 | 7,9 | 101 | | CVP | 7,33 | 0,14 | 30% | 5,13 | 9,53 | 101 | 99 | 98 |
| (12) Beckman Coulter | | 7,35 | 0,58 | 7,9 | 61 | 0 | | | | | | | 61 | | |
| (36) Immunotech | | 7,35 | 0,22 | 3 | 5 | 0 | | | | | | | 5 | | |
| (88) Becton Dickinson | | 7,4 | 0,8 | 11 | 12 | 0 | | | | | | | 12 | | |
| (177) Mindray | | 7,01 | 0,74 | 11 | 6 | 0 | | | | | | | 6 | | |
| (190) Exbio Praha | | 7,35 | 0,32 | 4,3 | 14 | 0 | | | | | | | 14 | | |
| Ostatní | | | | | 3 | 0 | | | | | | | 3 | | |
| | | | | | | | 3x 999 | | | | | | | | |

Cyklus EHK: IFT1/26 - Imunofenotypizace

Stop termín: 27.4.2026

Nastavení: skupiny - R (výrobce reagentů); minimální četnost skupin n = 5

| Zkouška Vzorek Skupina | [jednotka] | RoM | SD | CV [%] | N _{tot} | N _{out} | Srovnatelnost | | | | | N _{eva} | N _{suc} | S _{rel} [%] | |
|---|-----------------------|-------|-------|-----------|------------------|------------------|---------------|--|------------------|-----|-------|------------------|------------------|-------------------------|-----|
| | | | | | | | AV | U _{AV} | D _{max} | LL | UL | | | | |
| (257) NK buňky | [%] | | | | 101 | | | | | | | 101 | 97 | 96 | |
| Vzorek A | | 9,27 | 0,91 | 9,8 | 101 | | CVP | 9,27 | 0,22 | 26% | 6,85 | 11,7 | 101 | 99 | 98 |
| (12) Beckman Coulter | | 9,38 | 0,82 | 8,7 | 60 | 0 | | | | | | 60 | | | |
| (88) Becton Dickinson | | 9,22 | 0,97 | 11 | 13 | 0 | | | | | | 13 | | | |
| (177) Mindray | | 9,1 | 1 | 11 | 6 | 0 | | | | | | 6 | | | |
| (190) Exbio Praha | | 9,02 | 1,4 | 15 | 15 | 0 | | | | | | 15 | | | |
| Ostatní | | | | | 7 | 0 | | | | | | 7 | | | |
| | | | | | | | | 3x 36, 1x 64, 3x 999 | | | | | | | |
| Vzorek B | | 2,31 | 0,75 | 32 | 101 | | CVP | 2,31 | 0,18 | 64% | 0,831 | 3,79 | 101 | 97 | 96 |
| (12) Beckman Coulter | | 2,42 | 0,64 | 26 | 60 | 0 | | | | | | 60 | | | |
| (88) Becton Dickinson | | 2,16 | 0,85 | 39 | 13 | 0 | | | | | | 13 | | | |
| (177) Mindray | | 2,09 | 0,76 | 36 | 6 | 0 | | | | | | 6 | | | |
| (190) Exbio Praha | | 1,99 | 1 | 52 | 15 | 0 | | | | | | 15 | | | |
| Ostatní | | | | | 7 | 0 | | | | | | 7 | | | |
| | | | | | | | | 3x 36, 1x 64, 3x 999 | | | | | | | |
| (638) Izotypově přepnuté paměťové B lymfocyty (CD19+CD27+IgD-) | [% z B] | | | | 10 | | | | | | | 10 | 9 | 90 | |
| Vzorek A | | 24 | 9,6 | 40 | 10 | | CVP | 24 | 7,4 | 80% | 4,8 | 43,2 | 10 | 10 | 100 |
| (12) Beckman Coulter | | 23 | 11 | 47 | 7 | 0 | | | | | | 7 | | | |
| Ostatní | | | | | 3 | 0 | | | | | | 3 | | | |
| | | | | | | | | 1x 0, 1x 36, 1x 88 | | | | | | | |
| Vzorek B | | 18,1 | 5,5 | 30 | 10 | | CVP | 18,1 | 4,3 | 60% | 7,24 | 29 | 10 | 9 | 90 |
| (12) Beckman Coulter | | 17,8 | 6,7 | 38 | 7 | 0 | | | | | | 7 | | | |
| Ostatní | | | | | 3 | 0 | | | | | | 3 | | | |
| | | | | | | | | 1x 0, 1x 36, 1x 88 | | | | | | | |
| (642) T regulační lymfocyty (CD3+CD4+CD25+CD127low) | [% z Th] | | | | 16 | | | | | | | 16 | 15 | 94 | |
| Vzorek A | | 11,2 | 3 | 27 | 16 | | CVP | 11,2 | 1,8 | 54% | 5,15 | 17,3 | 16 | 15 | 94 |
| (12) Beckman Coulter | | 12 | 3,4 | 28 | 9 | 0 | | | | | | 9 | | | |
| Ostatní | | | | | 7 | 0 | | | | | | 7 | | | |
| | | | | | | | | 3x 0, 1x 36, 1x 88, 1x 190, 1x 999 | | | | | | | |
| Vzorek B | | 12 | 3,8 | 32 | 16 | | CVP | 12 | 2,3 | 64% | 4,32 | 19,7 | 16 | 15 | 94 |
| (12) Beckman Coulter | | 12,8 | 2 | 16 | 9 | 0 | | | | | | 9 | | | |
| Ostatní | | | | | 7 | 0 | | | | | | 7 | | | |
| | | | | | | | | 3x 0, 1x 36, 1x 88, 1x 190, 1x 999 | | | | | | | |
| (630) Leukocyty | [·10 ⁹ /L] | | | | 64 | | | | | | | 64 | 64 | 100 | |
| Vzorek A | | 3,26 | 0,12 | 3,7 | 64 | | CVP | 3,26 | 0,037 | 15% | 2,77 | 3,75 | 64 | 64 | 100 |
| (12) Beckman Coulter | | 3,12 | 0,11 | 3,7 | 7 | 0 | | | | | | 7 | | | |
| (63) Sysmex | | 3,3 | 0,11 | 3,4 | 42 | 0 | | | | | | 42 | | | |
| (177) Mindray | | 3,25 | 0,078 | 2,4 | 11 | 0 | | | | | | 11 | | | |
| Ostatní | | | | | 4 | 0 | | | | | | 4 | | | |
| | | | | | | | | 1x 1, 1x 176, 1x 179, 1x 190 | | | | | | | |
| Vzorek B | | 2,64 | 0,11 | 4,2 | 64 | | CVP | 2,64 | 0,034 | 15% | 2,24 | 3,04 | 64 | 64 | 100 |
| (12) Beckman Coulter | | 2,5 | 0,15 | 5,9 | 7 | 0 | | | | | | 7 | | | |
| (63) Sysmex | | 2,66 | 0,095 | 3,6 | 42 | 0 | | | | | | 42 | | | |
| (177) Mindray | | 2,66 | 0,11 | 4,1 | 11 | 0 | | | | | | 11 | | | |
| Ostatní | | | | | 4 | 0 | | | | | | 4 | | | |
| | | | | | | | | 1x 1, 1x 176, 1x 179, 1x 190 | | | | | | | |
| (631) Lymfocyty | [·10 ⁹ /L] | | | | 67 | | | | | | | 67 | 65 | 97 | |
| Vzorek A | | 1,47 | 0,16 | 11 | 67 | | CVP | 1,47 | 0,049 | 22% | 1,14 | 1,8 | 67 | 65 | 97 |
| (12) Beckman Coulter | | 1,35 | 0,097 | 7,2 | 10 | 0 | | | | | | 10 | | | |
| (63) Sysmex | | 1,55 | 0,16 | 10 | 39 | 0 | | | | | | 39 | | | |
| (177) Mindray | | 1,38 | 0,074 | 5,4 | 8 | 0 | | | | | | 8 | | | |
| Ostatní | | | | | 10 | 0 | | | | | | 10 | | | |
| | | | | | | | | 2x 0, 1x 1, 1x 36, 1x 88, 1x 176, 1x 179, 2x 190, 1x 999 | | | | | | | |
| Vzorek B | | 0,595 | 0,089 | 15 | 67 | | CVP | 0,595 | 0,027 | 30% | 0,416 | 0,774 | 67 | 65 | 97 |
| (12) Beckman Coulter | | 0,516 | 0,057 | 11 | 10 | 0 | | | | | | 10 | | | |
| (63) Sysmex | | 0,647 | 0,057 | 8,8 | 39 | 0 | | | | | | 39 | | | |
| (177) Mindray | | 0,515 | 0,052 | 10 | 8 | 0 | | | | | | 8 | | | |
| Ostatní | | | | | 10 | 0 | | | | | | 10 | | | |
| | | | | | | | | 2x 0, 1x 1, 1x 36, 1x 88, 1x 176, 1x 179, 2x 190, 1x 999 | | | | | | | |
| (632) T lymfocyty (CD3+) (abs. počet) | [·10 ⁹ /L] | | | | 66 | | | | | | | 66 | 62 | 94 | |
| Vzorek A | | 1,08 | 0,13 | 12 | 66 | | CVP | 1,08 | 0,038 | 24% | 0,82 | 1,34 | 66 | 62 | 94 |
| (12) Beckman Coulter | | 1,08 | 0,13 | 12 | 35 | 0 | | | | | | 35 | | | |
| (63) Sysmex | | 1,14 | 0,23 | 20 | 8 | 0 | | | | | | 8 | | | |
| (88) Becton Dickinson | | 1,09 | 0,054 | 5 | 5 | 0 | | | | | | 5 | | | |
| (190) Exbio Praha | | 1,11 | 0,13 | 11 | 7 | 0 | | | | | | 7 | | | |
| Ostatní | | | | | 11 | 0 | | | | | | 11 | | | |
| | | | | | | | | 4x 0, 2x 36, 2x 177, 3x 999 | | | | | | | |

Cyklus EHK: IFT1/26 - Imunofenotypizace

Stop termín: 27.4.2026

Nastavení: skupiny - R (výrobce reagentů); minimální četnost skupin n = 5

| Zkouška Vzorek Skupina | [jednotka] | RoM | SD | CV [%] | N _{tot} | N _{out} | Srovnatelnost | | | | | N _{eva} | N _{suc} | S _{rel} [%] | |
|---|----------------------------|-------|-------|-----------|------------------|------------------|-----------------------------------|-----------------|------------------|-----|-------|------------------|------------------|-------------------------|----|
| | | | | | | | AV | U _{AV} | D _{max} | LL | UL | | | | |
| Vzorek B | | 0,527 | 0,079 | 15 | 66 | | CVP | 0,527 | 0,024 | 30% | 0,368 | 0,686 | 66 | 64 | 97 |
| (12) Beckman Coulter | | 0,536 | 0,079 | 15 | 35 | 0 | | | | | | | 35 | | |
| (63) Sysmex | | 0,595 | 0,052 | 8,7 | 8 | 0 | | | | | | | 8 | | |
| (88) Becton Dickinson | | 0,53 | 0,045 | 8,4 | 5 | 0 | | | | | | | 5 | | |
| (190) Exbio Praha | | 0,547 | 0,093 | 17 | 7 | 0 | | | | | | | 7 | | |
| Ostatní | | | | | 11 | 0 | | | | | | | 11 | | |
| | | | | | | | 4x 0, 2x 36, 2x 177, 3x 999 | | | | | | | | |
| (633) Th lymfocyty (CD4+) (abs. počet) | [·10⁹/L] | | | | 66 | | | | | | | | 66 | 62 | 94 |
| Vzorek A | | 0,605 | 0,073 | 12 | 66 | | CVP | 0,605 | 0,022 | 24% | 0,459 | 0,751 | 66 | 62 | 94 |
| (12) Beckman Coulter | | 0,608 | 0,078 | 13 | 35 | 0 | | | | | | | 35 | | |
| (63) Sysmex | | 0,601 | 0,11 | 18 | 8 | 0 | | | | | | | 8 | | |
| (88) Becton Dickinson | | 0,618 | 0,042 | 6,7 | 5 | 0 | | | | | | | 5 | | |
| (190) Exbio Praha | | 0,625 | 0,067 | 11 | 7 | 0 | | | | | | | 7 | | |
| Ostatní | | | | | 11 | 0 | | | | | | | 11 | | |
| | | | | | | | 4x 0, 2x 36, 2x 177, 3x 999 | | | | | | | | |
| Vzorek B | | 0,386 | 0,056 | 15 | 66 | | CVP | 0,386 | 0,017 | 30% | 0,27 | 0,502 | 66 | 64 | 97 |
| (12) Beckman Coulter | | 0,392 | 0,056 | 14 | 35 | 0 | | | | | | | 35 | | |
| (63) Sysmex | | 0,43 | 0,045 | 10 | 8 | 0 | | | | | | | 8 | | |
| (88) Becton Dickinson | | 0,387 | 0,025 | 6,3 | 5 | 0 | | | | | | | 5 | | |
| (190) Exbio Praha | | 0,404 | 0,069 | 17 | 7 | 0 | | | | | | | 7 | | |
| Ostatní | | | | | 11 | 0 | | | | | | | 11 | | |
| | | | | | | | 4x 0, 2x 36, 2x 177, 3x 999 | | | | | | | | |
| (634) T lymfocyty (CD8+) (abs. počet) | [·10⁹/L] | | | | 66 | | | | | | | | 66 | 63 | 95 |
| Vzorek A | | 0,433 | 0,049 | 11 | 66 | | CVP | 0,433 | 0,015 | 22% | 0,337 | 0,529 | 66 | 64 | 97 |
| (12) Beckman Coulter | | 0,434 | 0,052 | 12 | 35 | 0 | | | | | | | 35 | | |
| (63) Sysmex | | 0,445 | 0,052 | 12 | 8 | 0 | | | | | | | 8 | | |
| (88) Becton Dickinson | | 0,437 | 0,013 | 2,9 | 5 | 0 | | | | | | | 5 | | |
| (190) Exbio Praha | | 0,45 | 0,059 | 13 | 7 | 0 | | | | | | | 7 | | |
| Ostatní | | | | | 11 | 0 | | | | | | | 11 | | |
| | | | | | | | 4x 0, 2x 36, 2x 177, 3x 999 | | | | | | | | |
| Vzorek B | | 0,123 | 0,02 | 16 | 66 | | CVP | 0,123 | 0,006 | 32% | 0,083 | 0,163 | 66 | 63 | 95 |
| (12) Beckman Coulter | | 0,125 | 0,018 | 14 | 35 | 0 | | | | | | | 35 | | |
| (63) Sysmex | | 0,144 | 0,009 | 6,2 | 8 | 0 | | | | | | | 8 | | |
| (88) Becton Dickinson | | 0,122 | 0,015 | 12 | 5 | 0 | | | | | | | 5 | | |
| (190) Exbio Praha | | 0,126 | 0,022 | 17 | 7 | 0 | | | | | | | 7 | | |
| Ostatní | | | | | 11 | 0 | | | | | | | 11 | | |
| | | | | | | | 4x 0, 2x 36, 2x 177, 3x 999 | | | | | | | | |
| (635) B lymfocyty (abs. počet) | [·10⁹/L] | | | | 66 | | | | | | | | 66 | 59 | 89 |
| Vzorek A | | 0,232 | 0,031 | 13 | 66 | | CVP | 0,232 | 0,009 | 26% | 0,171 | 0,293 | 66 | 61 | 92 |
| (12) Beckman Coulter | | 0,233 | 0,032 | 14 | 35 | 0 | | | | | | | 35 | | |
| (63) Sysmex | | 0,25 | 0,045 | 18 | 8 | 0 | | | | | | | 8 | | |
| (88) Becton Dickinson | | 0,247 | 0,025 | 9,9 | 5 | 0 | | | | | | | 5 | | |
| (190) Exbio Praha | | 0,244 | 0,025 | 10 | 7 | 0 | | | | | | | 7 | | |
| Ostatní | | | | | 11 | 0 | | | | | | | 11 | | |
| | | | | | | | 4x 0, 2x 36, 2x 177, 3x 999 | | | | | | | | |
| Vzorek B | | 0,043 | 0,007 | 17 | 66 | | CVP | 0,043 | 0,002 | 34% | 0,028 | 0,058 | 66 | 61 | 92 |
| (12) Beckman Coulter | | 0,045 | 0,008 | 17 | 35 | 0 | | | | | | | 35 | | |
| (63) Sysmex | | 0,047 | 0,004 | 9,4 | 8 | 0 | | | | | | | 8 | | |
| (88) Becton Dickinson | | 0,04 | 0 | 0 | 5 | 0 | | | | | | | 5 | | |
| (190) Exbio Praha | | 0,045 | 0,008 | 18 | 7 | 0 | | | | | | | 7 | | |
| Ostatní | | | | | 11 | 0 | | | | | | | 11 | | |
| | | | | | | | 4x 0, 2x 36, 2x 177, 3x 999 | | | | | | | | |
| (636) NK buňky (abs. počet) | [·10⁹/L] | | | | 66 | | | | | | | | 66 | 59 | 89 |
| Vzorek A | | 0,139 | 0,021 | 15 | 66 | | CVP | 0,139 | 0,006 | 30% | 0,097 | 0,181 | 66 | 61 | 92 |
| (12) Beckman Coulter | | 0,14 | 0,022 | 16 | 34 | 0 | | | | | | | 34 | | |
| (63) Sysmex | | 0,15 | 0,015 | 9,9 | 8 | 0 | | | | | | | 8 | | |
| (88) Becton Dickinson | | 0,133 | 0,004 | 2,8 | 5 | 0 | | | | | | | 5 | | |
| (190) Exbio Praha | | 0,145 | 0,022 | 15 | 7 | 0 | | | | | | | 7 | | |
| Ostatní | | | | | 12 | 0 | | | | | | | 12 | | |
| | | | | | | | 4x 0, 1x 9, 2x 36, 2x 177, 3x 999 | | | | | | | | |
| Vzorek B | | 0,014 | 0,006 | 44 | 66 | | CVP | 0,014 | 0,002 | 88% | 0,001 | 0,027 | 66 | 60 | 91 |
| (12) Beckman Coulter | | 0,015 | 0,007 | 45 | 34 | 0 | | | | | | | 34 | | |
| (63) Sysmex | | 0,015 | 0,007 | 49 | 8 | 0 | | | | | | | 8 | | |
| (88) Becton Dickinson | | 0,012 | 0,003 | 25 | 5 | 0 | | | | | | | 5 | | |
| (190) Exbio Praha | | 0,014 | 0,009 | 64 | 7 | 0 | | | | | | | 7 | | |
| Ostatní | | | | | 12 | 0 | | | | | | | 12 | | |
| | | | | | | | 4x 0, 1x 9, 2x 36, 2x 177, 3x 999 | | | | | | | | |